Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

PHASE1

Phase

COMPLETED

Status

Enrollment

INDUSTRY

Sponsor class

Conditions

DRUG: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed
DRUG: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted
DRUG: Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed
DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast
DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast
DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast

Bayer